Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: Reassessment of risk factors for tumor recurrence

Annals of Surgery

Volumn 248, Issue 5, 2008, Pages 857-862

  Vivarelli, Marco ^a   Cucchetti, Alessandro ^a   Barba, Giuliano La ^a   Ravaioli, Matteo ^a   Del Gaudio, Massimo ^a   Lauro, Augusto ^a   Grazi, Gian Luca ^a   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CYCLOSPORIN; TACROLIMUS; CALCINEURIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; BLOOD; DRUG ANTAGONISM; IMMUNOLOGY; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ADULT; ALPHA-FETOPROTEINS; CALCINEURIN; CARCINOMA, HEPATOCELLULAR; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TACROLIMUS;

EID: 56149097732     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181896278     Document Type: Article

References (24)

1. Iwatsuki S, Gordon RD, Shaw BW, et al. Role of liver transplantation in cancer therapy. Ann Surg. 1985;202:401-407.
2. O'Grady JG, Polson RJ, Rolles K, et al. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg. 1988;207:373-379.
3. Ringe B, Wittekind C, Bechstein WO, et al. The role of liver transplantation in hepatobiliary malignancy: a retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg. 1989;209:88-98.
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Eng J Med. 1996;334:693-699.
5. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.
6. Esnaola NF, Lauwers GY, Mirza NQ, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg. 2002;6:224-232.
7. Fiorentino M, Altimari A, Ravaioli M, et al. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin Cancer Res. 2004;10:1789-1795.
8. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg. 2004;239:150-159.
9. Vivarelli M, Bellusci R, Cucchetti A, et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation. 2002;74:1746-1751.
10. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl. 2005;11:497-503.
11. Edmondson HA, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
12. AJCC Cancer Staging Handbook. 6th ed. New York, NY: Springer; 2002:145-153.
13. Hanley JA. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging. 1989;29:307-335.
14. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation. 1993;55:742-747.
15. Yokoyama I, Carr B, Saitsu H, et al. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer. 1991;68:2095-2100.
16. Freise CE, Ferrell L, Liu T, et al. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation. 1999;67:510-513.
17. Guba M, Graeb C, Jauch KW, et al. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004;77:1777-1782.
18. Sotiropoulos GC, Malago M, Molmenti E, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classi?cation before transplantation realistic? Transplantation. 2005;79:483-487.
19. Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl. 2006;12:1504-1511.
20. Shah SA, Tan JC, McGilvray ID, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation. 2006;81:1633-1639.
21. Grasso A, Stigliano R, Morisco F, et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation. 2006;81:1532-1541.
22. Bernal E, Montero JL, Delgado M, et al. Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc. 2006;38:2495-2489.
23. Schwartz M, Konstadoulakis M, Roayaie S. Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl. 2005;11:494-496.
24. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. 2004;10:1301-1311.